Analysts Boost Price Targets After FDA Approves First-in-Class Pancreatic Cancer Drug
RVMD has more than doubled off its 52-week low of $35.637.
Summary
The FDA approved Rasonque (daraxonrasib) for previously treated metastatic pancreatic cancer, making it the first approved targeted therapy in a new class of broad RAS-selective inhibitors. The approval was based on Phase 3 data showing a 60% reduction in risk of death and nearly doubled median overall survival (13.2 vs 6.7 months). Following the decision, six Wall Street firms raised price targets, with Evercore ISI going to $320 and HC Wainwright to $280. The stock is trading up 1.66% at $219.01, near its 52-week high. This follows the company's Q2 net loss of $644M and recent insider sales under 10b5-1 plans, but the approval validates the pipeline and could drive significant revenue. Watch for global regulatory submissions and commercial launch execution.
At the time of this announcement, RVMD was trading at $220.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.3B. The 52-week trading range was $35.64 to $224.31. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.